EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT ID: NCT00636155

Last Updated: 2012-11-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2012-05-31

Brief Summary

The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Detailed Description

Chronic lymphocytic leukemia (CLL) and small B-cell lymphocytic lymphoma (SLL) are thought to be different manifestations of the same disease. Treatment options for CLL/SLL range from a watch and wait approach to bone marrow transplant. Currently there is no consensus on the best treatment regimen and new approaches to treatment are needed.

EL625 is a 20-mer antisense molecule which binds to a coding region of exon 10 in p53 RNA transcripts. It can bind to both mutant and wild type p53. p53 is involved in regulating apoptosis and DNA repair in cells. When genetic damage occurs p53 is upregulated. As the expression of p53 increases in normal cells they are more likely to undergo apoptosis rather than cell cycle arrest and DNA repair. However in malignant cells, for a given level of DNA damage they are more likely to undergo cell cycle arrest and repair rather than apoptosis. Because EL625 is theorized to increase response to chemotherapy, we propose adding EL625 to a combination of fludarabine, cyclophosphamide and rituximab.

Conditions

Lymphoma, Small Lymphocytic; Leukemia, Lymphocytic, Chronic

Keywords

Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; EL625; cenersen

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

all patients

EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)

Group Type: EXPERIMENTAL

cenersen sodium

Intervention Type: DRUG

2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

Rituximab

Intervention Type: DRUG

375 mg/m2 on day 2

Cyclophosphamide

Intervention Type: DRUG

250 mg/m2 on days 2, 3, and 4

Fludarabine

Intervention Type: DRUG

25 mg/m2 on days 2, 3, and 4

Interventions

cenersen sodium

2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

Intervention Type: DRUG

Rituximab

375 mg/m2 on day 2

Intervention Type: DRUG

Cyclophosphamide

250 mg/m2 on days 2, 3, and 4

Intervention Type: DRUG

Fludarabine

25 mg/m2 on days 2, 3, and 4

Intervention Type: DRUG

Other Intervention Names

EL625; Rituxan; Cytoxan; Fludara

Eligibility Criteria

Inclusion Criteria

• Patients with a diagnosis of CLL/SLL who have received at least one prior treatment regimen and have persistent disease (i.e. any evidence of active disease). Patients with a chromosome 17 abnormality or a p53 mutation of any type may be enrolled without having received prior treatment.
• Patients must be 18 years of age or older.
• Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment.
• AST, ALT, total bilirubin < than 2.5 times the upper limit of normal.
• WBC > 1.5; ANC >500; Plt >50,000 unless documented as due to disease
• ECOG performance status of 0-2.
• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
• Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for 2 weeks after administration of the study drug.
• Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after administration of study drug.

Exclusion Criteria

• Female who is pregnant or lactating.
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Patients with another malignancy within the last three years (from documentation of remission) other than basal or squamous cell skin cancer, resected early stage prostate cancer not requiring systemic treatment or CIS of the cervix or fully treated early stage prostate cancer.
• Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NYHA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation.
• Patients who are unable to refrain from taking acetaminophen
• Investigational agent within 14 days of enrolling on the study.
• Patients unable or unwilling to refrain from antioxidants including vitamin A, vitamin C, vitamin E, lycopene, lutein, grape seed extract, pycnogenol, green tea extract, and the like.
• Patients who have received a prior allogenic stem cell transplant and have at least 2.5% donor cells still evident on engraftment studies.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eleos, Inc.

INDUSTRY

Sponsor Role: collaborator

David Rizzieri

OTHER

Sponsor Role: lead

Responsible Party

David Rizzieri

Associate Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

David Rizzieri, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Duke University Medical Center

Durham, North Carolina, United States

Countries

United States

Other Identifiers

Pro00001363

Identifier Type: -

Identifier Source: org_study_id